GlassScriptPhysician profile
Hoda Butrous
NPI 1093005514
$4,164.92
in general payments reported to CMS, 2019-2025
17 companies · $744 in 2025
The $744 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,447 · 2020: $791 · 2021: $11.67 · 2022: $114 · 2023: $40.87 · 2024: $17.06 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763 · Travel and Lodging: $38.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.44 |
| Travel and Lodging | $38.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,100.75 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic Vascular, INC. | $1,038.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $443.39 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $332.65 | 2019-2020 | |
| Pfizer INC. | $291.37 | 2019-2025 | |
| United Therapeutics Corporation | $180.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $179.96 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $109.14 | 2019 | |
| Nuwellis, INC. | $106.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $90.67 | 2019-2025 | Wainua |
| Amgen INC. | $76.66 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $54.92 | 2019-2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $44.06 | 2019 | |
| Sandoz INC. | $34.89 | 2019-2020 | |
| Boston Scientific Corporation | $34.30 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.02 | 2020 | |
| Vifor Pharma, INC. | $19.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoda Butrous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.